BACKGROUND: Pulmonary alveolar proteinosis (PAP) is a rare disease characterised by accumulation of lipoproteinaceous material within alveoli, occurring in three clinically distinct forms: congenital, acquired and secondary. Among the latter, lysinuric protein intolerance (LPI) is a rare genetic disorder caused by defective transport of cationic amino acids. Whole Lung Lavage (WLL) is currently the gold standard therapy for severe cases of PAP. CASE PRESENTATION: We describe the case of an Italian boy affected by LPI who, by the age of 10, developed digital clubbing and, by the age of 16, a mild restrictive functional impairment associated with a high-resolution computed tomography (HRCT) pattern consistent with pulmonary alveolar proteinos...
Pulmonary Alveolar Proteinosis (PAP) is a rare disease, 3.2-6.7 cases per million. It is caused by P...
Pulmonary alveolar proteinosis (PAP) – an unusual diffuse lung disease characterized by alveolar acc...
New therapies have emerged in the treatment of pulmonary alveolar proteinosis (PAP) and, therefore, ...
Pulmonary alveolar proteinosis (PAP) is a rare disease in children characterized by intra-alveolar a...
Background: Pulmonary alveolar proteinosis (PAP) is a rare disease in children, characterized by int...
ABSTRACT Background: Pulmonary Alveolar Proteinosis (PAP) is a rare pulmonary disorder caused by a c...
[Pulmonary alveolar proteinosis]. Pulmonary alveolar proteinosis (PAP) is a rare, diffuse infiltrati...
Objective: The aim of this study was to present the evolution of four patients presenting pulmonary ...
ABSTRACT Objective: Pulmonary alveolar proteinosis (PAP) is a rare disease, characterized by the al...
ABSTRACT: Pulmonary Alveolar Proteinosis (PAP) is a rare syndrome characterized by pulmonary surfact...
Pulmonary Alveolar Proteinosis (PAP) is a rare syndrome characterized by pulmonary surfactant accumu...
SummaryGonçalves BM, Teixeira VC, Bittencourt PFS – Anesthesia for Lung Lavage in Pediatric Patients...
This case report demonstrates 44-year old man, presenting with recurring clinical pneumonias during ...
Pulmonary alveolar proteinosis (PAP) is a rare disorder in which lipoproteinaceous material is depos...
AbstractIdiopathic pulmonary alveolar proteinosis (PAP) is a rare disease due to impaired alveolar m...
Pulmonary Alveolar Proteinosis (PAP) is a rare disease, 3.2-6.7 cases per million. It is caused by P...
Pulmonary alveolar proteinosis (PAP) – an unusual diffuse lung disease characterized by alveolar acc...
New therapies have emerged in the treatment of pulmonary alveolar proteinosis (PAP) and, therefore, ...
Pulmonary alveolar proteinosis (PAP) is a rare disease in children characterized by intra-alveolar a...
Background: Pulmonary alveolar proteinosis (PAP) is a rare disease in children, characterized by int...
ABSTRACT Background: Pulmonary Alveolar Proteinosis (PAP) is a rare pulmonary disorder caused by a c...
[Pulmonary alveolar proteinosis]. Pulmonary alveolar proteinosis (PAP) is a rare, diffuse infiltrati...
Objective: The aim of this study was to present the evolution of four patients presenting pulmonary ...
ABSTRACT Objective: Pulmonary alveolar proteinosis (PAP) is a rare disease, characterized by the al...
ABSTRACT: Pulmonary Alveolar Proteinosis (PAP) is a rare syndrome characterized by pulmonary surfact...
Pulmonary Alveolar Proteinosis (PAP) is a rare syndrome characterized by pulmonary surfactant accumu...
SummaryGonçalves BM, Teixeira VC, Bittencourt PFS – Anesthesia for Lung Lavage in Pediatric Patients...
This case report demonstrates 44-year old man, presenting with recurring clinical pneumonias during ...
Pulmonary alveolar proteinosis (PAP) is a rare disorder in which lipoproteinaceous material is depos...
AbstractIdiopathic pulmonary alveolar proteinosis (PAP) is a rare disease due to impaired alveolar m...
Pulmonary Alveolar Proteinosis (PAP) is a rare disease, 3.2-6.7 cases per million. It is caused by P...
Pulmonary alveolar proteinosis (PAP) – an unusual diffuse lung disease characterized by alveolar acc...
New therapies have emerged in the treatment of pulmonary alveolar proteinosis (PAP) and, therefore, ...